Repligen Corp
RGEN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000730272
In the last 90 days, Repligen Corp insiders filed 0 open-market purchases and 5 sales; 481 institutions reported holding it in 13F filings for Q2 2026, worth $9.00B in total; 3 superinvestors hold it, including Maverick Capital and Duquesne Family Office.
13F holders, Q2 2025
Institutional positions in Repligen Corp as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 446
- +7 vs. Q1 2025
- Shares held
- 58.4M
- +830.1K (+1.4%) vs. Q1 2025
- Total value
- $7.22B
- −$108.0M (−1.5%) vs. Q1 2025
- New holders
- 75
- 130 more added
- Sold out
- 68
- 174 more reduced
2 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RGEN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 481 | $9.00B |
| Q1 2026 | 445 | $7.75B |
| Q4 2025 | 475 | $10.2B |
| Q3 2025 | 453 | $8.00B |
| Q2 2025 | 446 | $7.22B |
| Q1 2025 | 441 | $7.33B |
| Q4 2024 | 431 | $8.09B |
| Q3 2024 | 445 | $8.25B |
| Q2 2024 | 455 | $7.06B |
| Q1 2024 | 487 | $10.3B |
| Q4 2023 | 467 | $10.4B |
| Q3 2023 | 440 | $9.08B |
| Q2 2023 | 448 | $7.74B |
| Q1 2023 | 448 | $9.06B |
| Q4 2022 | 443 | $9.06B |
| Q3 2022 | 434 | $9.56B |
| Q2 2022 | 406 | $8.17B |
| Q1 2022 | 450 | $9.15B |
| Q4 2021 | 508 | $12.5B |
| Q3 2021 | 481 | $13.6B |
| Q2 2021 | 430 | $9.28B |
| Q1 2021 | 459 | $8.88B |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Repligen Corp; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −19−100.0% | Sold out |
| Grove Bank & Trust | 0 | $0 | 0.00% | −19−100.0% | Sold out |
| Carolinas Wealth Consulting LLC | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Red Tortoise LLC | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Hughes Financial Services, LLC | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Cornerstone Planning Group LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Bogart Wealth, LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Global Financial Private Client, LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Riggs Asset Managment Co. Inc. | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| WealthTrak Capital Management LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Bruce G. Allen Investments, LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Financial Management Professionals, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Glenmede Trust Co NA | – | – | – | – | Not filed |
| Lindbrook Capital, LLC | – | – | – | – | Not filed |